[CAS NO. 1445385-02-3] Lumicitabine
PRODUCTS SPECIFICATIONS [1445385-02-3]
DESCRIPTION [1445385-02-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 433.86 |
| Molecular Formula | C18H25ClFN3O6 |
| SMILES | ClC[C@@]1(COC(C(C)C)=O)[C@@H](OC(C(C)C)=O)[C@@H](F)[C@H](N2C(N=C(N)C=C2)=O)O1 |
Summary
Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus ( RSV ) polymerase.
In Vitro
Lumicitabine is an orally bioavailable prodrug of the novel RSV replication inhibitor ALS-008112, a cytidine nucleoside analogue [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Lumicitabine demonstrates excellent anti-RSV efficacy and safety in a phase 2 clinical RSV challenge study. It exhibits good oral bioavailability and a high level of 2c-TP in vivo . Lumicitabine has excellent stability profiles in formulations (>24 h storage stability in 0.5% methylcellulose aqueous formulation at rt) and simulats gastric and intestinal fluids (half-life >2 h). Its solubility is adequate to support oral administration in solutions with relatively low percentage of organic solvent and in aqueous suspensions. High levels of NMP and NTP are obtained following oral administration of Lumicitabine to monkeys [2] . In an adult human challenge study, Lumicitabine has shown efficacy against RSV infection [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02094365 | Alios Biopharma Inc. |
Respiratory Syncytial Virus Infections
|
March 2014 | Phase 2 |
| NCT01906164 | Alios Biopharma Inc. |
Respiratory Syncytial Virus Infections
|
May 31, 2013 | Phase 1 |
| NCT02833831 | Janssen Research & Development, LLC |
Healthy
|
June 2, 2016 | Phase 1 |
| NCT02813460 | Janssen Research & Development, LLC |
Healthy
|
June 2016 | Phase 1 |
| NCT03332459 | Janssen Research & Development, LLC |
Respiratory Syncytial Virus Infections
|
January 5, 2018 | Phase 2 |
| NCT02478333 | Janssen Pharmaceutical K.K. |
Respiratory Syncytial Virus Infections
|
May 2015 | Phase 1 |
| NCT02935673 | Janssen Research & Development, LLC |
Respiratory Syncytial Viruses
|
October 25, 2016 | Phase 2 |
| NCT02231671 | Alios Biopharma Inc. |
Respiratory Syncytial Virus Infections
|
August 31, 2014 | Phase 1 |
| NCT03468777 | Janssen Research & Development, LLC |
Healthy
|
March 6, 2018 | Phase 1 |
| NCT03441529 | Janssen Research & Development, LLC |
Healthy
|
February 9, 2018 | Phase 1 |
| NCT03502694 | Janssen Research & Development, LLC |
Metapneumovirus
|
November 5, 2018 | Phase 2 |
| NCT02202356 | Alios Biopharma Inc. |
Respiratory Syncytial Virus Infections
|
July 23, 2014 | Phase 1 |
| NCT02673476 | Alios Biopharma Inc. |
Respiratory Syncytial Virus Infections
|
February 29, 2016 | Phase 2 |
| NCT03333317 | Janssen Research & Development, LLC |
Respiratory Syncytial Viruses
|
November 24, 2017 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 50 mg/mL ( 115.24 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3049 mL | 11.5245 mL | 23.0489 mL |
| 5 mM | 0.4610 mL | 2.3049 mL | 4.6098 mL |
| 10 mM | 0.2305 mL | 1.1524 mL | 2.3049 mL |
References
- [1] DeVincenzo JP, et al. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. N Engl J Med. 2015 Nov 19;373(21):2048-58.
- [2] Wang G, et al. Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem. 2015 Feb 26;58(4):1862-78.